Skip to main content
HALO logo
HALO
(NASDAQ)
Halozyme Therapeutics, Inc.
$107.00-- (--)
Loading... - Market loading

Halozyme Therapeutics, Inc. (HALO) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Halozyme Therapeutics, Inc. stock.

Analyst Consensus Rating

Investment consensus from 4 professional research analysts

Consensus Rating

Buy
Based on 4 unique analysts
Low Confidence2.0:1 Buy/Sell

Average Price Target

$80.00
25.51% Downside

Loading chart...

Strong Sell
Sell
Hold
Buy
Strong Buy

Latest HALO Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Mitchell Kapoor
HC Wainwright
BuyReiterates
$95.00
Corinne Johnson
Goldman Sachs
SellMaintains
$57.00
Mohit Bansal
Wells Fargo
HoldReiterates
$75.00
Sean Laaman
Morgan Stanley
BuyMaintains
$93.00

Frequently Asked Questions

What is the analyst consensus rating for HALO?

The analyst consensus rating for HALO is "Buy" based on 4 analyst recommendations.

What is the average price target for HALO?

The average 12-month price target for HALO is $80.00, representing a downside of 25.5% from the current price of $107.39.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.